Trial Profile
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Acronyms TRAVERSE
- Sponsors Sanofi
- 09 Feb 2024 According to a Sanofi media release, 96-week long term data from this trial will be presented at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting from February 23 to 26.
- 24 May 2023 Results assessing long-term safety of dupilumab in patients who completed 96 weeks presented at the 119th International Conference of the American Thoracic Society
- 31 Mar 2022 Status changed from active, no longer recruiting to completed.